Medgenics Inc: JMP Securities assumed coverage on shares of Medgenics (NYSEMKT:MDGN) in a research note issued to investors on Monday The firm issued an outperform rating on the stock.
Separately, analysts at Piper Jaffray raised their price target on shares of Medgenics from $7.00 to $11.50 and gave the company a buy rating in a research note on Tuesday, January 20th.
Shares of Medgenics (NYSEMKT:MDGN) opened at 8.69 on Monday. Medgenics has a 1-year low of $3.68 and a 1-year high of $8.80. The stock’s 50-day moving average is $8. and its 200-day moving average is $6.. The company’s market cap is $215.45 million.
Medgenics (NYSEMKT:MDGN) last announced its earnings results on Friday, February 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.08.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.